OnCoCross Co EBITDA TCAC 5A

Que fait OnCoCross Co ? OnCoCross Co Ltd develops an AI-driven platform for new drug research and development, focusing on analyzing gene expression data to match optimal disease treatments. The company targets rare diseases, cancer, and dementia through its original technology, creating solutions for intractable conditions. Its primary revenue comes from licensing the AI platform to pharmaceutical companies and research institutions seeking advanced drug discovery tools. The firm serves clients in the biotechnology sector who require innovative approaches to develop treatments for complex medical challenges. The company's platform enables precise matching of drug candidates to specific diseases by processing transcriptome data, which is critical for developing targeted therapies. Pharmaceutical firms and research organizations purchase the AI platform to accelerate their R&D processes, reducing time and costs associated with traditional drug development. This service is particularly valuable for addressing rare and complex diseases where conventional methods have limited success. OnCoCross Co Ltd's business model centers on providing a specialized AI solution that transforms how drug development is approached, especially for diseases with high unmet medical needs. By leveraging its proprietary technology, the company offers a unique value proposition to biotech and pharmaceutical companies aiming to innovate in treatment development. The focus on rare diseases and cancer positions the firm as a key player in advancing personalized medicine solutions. OnCoCross Co est l'une des entreprises les plus populaires sur Eulerpool.